Absalón AD, Serrano-Lozano JA, Gutiérrez-Díaz CA

Language: Spanish
References: 14
Page: 109-115
PDF size: 162.77 Kb.

ABSTRACT

Background. post-thrombotic syndrome (PTS) is a chronic complication that presents in almost 30% of patients with DVT after treatment with E+A. In the functional point of view, patients complain important limitations in their daily activities affecting their quality of life. Rivaroxaban has been an effective treatment for DVT. However, it has not been shown its use for the prevention of PTS.
Objective. Compare the effectiveness of rivaroxaban (R) against enoxaparin plus acenocoumarin (E+A) in the prevention of PTS in femoropopliteal deep venous thrombosis (DVT).
Material and methods. Patients with femoropopliteal DVT diagnosed by Doppler ultrasound, we stablished a randomized treatment with R or E+A. Evaluated patients at one, three and six monthsViwith Villalta scale. Follow up with ultrasound at the third and sixth month to verify recanalization and reflux.
Results. 160 patients completed the study. Rivaroxaban reduced the risk of PTS (mild and moderate) in a 16.3% (CI95% of 2.3 to 29.4%) at the first month, a 20% (CI95% of 6.2 to 32.9%) at the third month and 16.2% (CI95% of 2.9 to 28.9%) at the sixth month. In 90% of the patients that developed PTS was mild, the rest moderate (Villalta score). There was a bigger percentage of venous recanalization in the Rivaroxaban group with a lower incidence of reflux.
Conclusion. The use of rivaroxaban in patients with femoro-popliteal DVT, reduce the risk of presenting PTS and has a better recanalization.

REFERENCES

1. The EINSTEIN Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010; 363: 2499-510.

2. Oger E. Incidence of venous thromboembolism: a community- based study in Western France. Thromb Haemost 2000; 83: 657-60.

3. Van Dongen CJJ, Prandoni P, Frulla M, et al. Relation between quality of antithrombotic treatment and the development of the post-thrombotic syndrome. J Thromb Haemost 2005; 3: 939-42.

4. Kahn Sr, Shrier I, Julian JA. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.

5. Prandoni P, Lensing AW, Cogo A, Prins MH, Frulla M, Marchiori A, Bernardi E, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized controlled trial. Ann Intern Med 2004; 141: 249-56.

6. Kahn SR, Ducret T, Lamping DL, Arsenault L, Miron MJ, Roussin A, et al. Prospective evaluation of health related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005; 165: 1173-8.

7. Yamaki T, Hamahata A, Soejima K, Kono T, Nozaki M, Sakurai H. Factors predicting development pf postthrombotic syndrome in patients with a first episode of vein thrombosis: Preliminary report. Eur J Endovasc Surg 2011; 41: 126-33.

8. Kahn SR, Partsh H, Vedantham S, Prandoni P, Kearon C. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7: 879-83.

9. Henke PK, Comerota AJ. An update on etiology, prevention, and therapy of post-thrombotic syndrome. J Vasc Surg 2011; 53: 500-09.

10. Ordovás JP, Climent E, Jover A, Valero I. Farmacocinética y farmacodinamia de los nuevos anticoagulantes orales. Farm Hosp 2009; 33(3): 125-33.

11. Ziegler S, Shiller M, Maca TH, Minar E. Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. J Thromb Haemost 2005; 3: 2671-7.

12. Asbeutah AM, Riha AZ, Cameron JD, McGrath BP. Five year outcome study of deep vein thrombosis in the lower limbs. J Vasc Surg 2004; 40: 1184-9.

13. González Fajardo JA, Martín-Pedrosa M, Castrodeza J, et al. Effect of anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. J Vasc Surg 2008; 48: 953.

14. Einstein PE. Rivaroxaban oral para el tratamiento de la embolia pulmonar sintomática. N Engl J Med 2012; 366: 1287-97.